Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound
Histotripsy is the first noninvasive, non-ionizing, and non-thermal ablation technology guided by real-time imaging. Using focused ultrasound delivered from outside the body, histotripsy mechanically destroys tissue through cavitation, rendering the target into acellular debris. The material in the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/02656736.2021.1905189 |
| id |
doaj-34e00540de0b47dba37180f8ac58c958 |
|---|---|
| record_format |
Article |
| spelling |
doaj-34e00540de0b47dba37180f8ac58c9582021-04-21T16:14:20ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572021-01-0138156157510.1080/02656736.2021.19051891905189Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasoundZhen Xu0Timothy L. Hall1Eli Vlaisavljevich2Fred T. Lee3Department of Biomedical Engineering, University of MichiganDepartment of Biomedical Engineering, University of MichiganDepartment of Biomedical Engineering and Mechanics, Virginia Polytechnic Institute and State UniversityDepartments of Radiology, Biomedical Engineering, and Urology, University of WisconsinHistotripsy is the first noninvasive, non-ionizing, and non-thermal ablation technology guided by real-time imaging. Using focused ultrasound delivered from outside the body, histotripsy mechanically destroys tissue through cavitation, rendering the target into acellular debris. The material in the histotripsy ablation zone is absorbed by the body within 1–2 months, leaving a minimal remnant scar. Histotripsy has also been shown to stimulate an immune response and induce abscopal effects in animal models, which may have positive implications for future cancer treatment. Histotripsy has been investigated for a wide range of applications in preclinical studies, including the treatment of cancer, neurological diseases, and cardiovascular diseases. Three human clinical trials have been undertaken using histotripsy for the treatment of benign prostatic hyperplasia, liver cancer, and calcified valve stenosis. This review provides a comprehensive overview of histotripsy covering the origin, mechanism, bioeffects, parameters, instruments, and the latest results on preclinical and human studies.http://dx.doi.org/10.1080/02656736.2021.1905189high intensity ultrasoundultrasoundphysicsimagingimmunotherapy |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Zhen Xu Timothy L. Hall Eli Vlaisavljevich Fred T. Lee |
| spellingShingle |
Zhen Xu Timothy L. Hall Eli Vlaisavljevich Fred T. Lee Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound International Journal of Hyperthermia high intensity ultrasound ultrasound physics imaging immunotherapy |
| author_facet |
Zhen Xu Timothy L. Hall Eli Vlaisavljevich Fred T. Lee |
| author_sort |
Zhen Xu |
| title |
Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound |
| title_short |
Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound |
| title_full |
Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound |
| title_fullStr |
Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound |
| title_full_unstemmed |
Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound |
| title_sort |
histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound |
| publisher |
Taylor & Francis Group |
| series |
International Journal of Hyperthermia |
| issn |
0265-6736 1464-5157 |
| publishDate |
2021-01-01 |
| description |
Histotripsy is the first noninvasive, non-ionizing, and non-thermal ablation technology guided by real-time imaging. Using focused ultrasound delivered from outside the body, histotripsy mechanically destroys tissue through cavitation, rendering the target into acellular debris. The material in the histotripsy ablation zone is absorbed by the body within 1–2 months, leaving a minimal remnant scar. Histotripsy has also been shown to stimulate an immune response and induce abscopal effects in animal models, which may have positive implications for future cancer treatment. Histotripsy has been investigated for a wide range of applications in preclinical studies, including the treatment of cancer, neurological diseases, and cardiovascular diseases. Three human clinical trials have been undertaken using histotripsy for the treatment of benign prostatic hyperplasia, liver cancer, and calcified valve stenosis. This review provides a comprehensive overview of histotripsy covering the origin, mechanism, bioeffects, parameters, instruments, and the latest results on preclinical and human studies. |
| topic |
high intensity ultrasound ultrasound physics imaging immunotherapy |
| url |
http://dx.doi.org/10.1080/02656736.2021.1905189 |
| work_keys_str_mv |
AT zhenxu histotripsythefirstnoninvasivenonionizingnonthermalablationtechniquebasedonultrasound AT timothylhall histotripsythefirstnoninvasivenonionizingnonthermalablationtechniquebasedonultrasound AT elivlaisavljevich histotripsythefirstnoninvasivenonionizingnonthermalablationtechniquebasedonultrasound AT fredtlee histotripsythefirstnoninvasivenonionizingnonthermalablationtechniquebasedonultrasound |
| _version_ |
1721516083865714688 |